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The vast amount of biological knowledge accumulated over the
years has allowed researchers to identify various biochemical interac-
tions and define different families of pathways. There is an increased
interest in identifying pathways and pathway elements involved in
particular biological processes. Drug discovery efforts, for example,
are focused on identifying biomarkers as well as pathways related to
a disease. We propose a Bayesian model that addresses this ques-
tion by incorporating information on pathways and gene networks
in the analysis of DNA microarray data. Such information is used
to define pathway summaries, specify prior distributions, and struc-
ture the MCMC moves to fit the model. We illustrate the method
with an application to gene expression data with censored survival
outcomes. In addition to identifying markers that would have been
missed otherwise and improving prediction accuracy, the integration
of existing biological knowledge into the analysis provides a better
understanding of underlying molecular processes.
1. Introduction. DNA microarrays have been used successfully to iden-
tify gene expression signatures characteristic of disease subtypes [Golub et al.
(1999)] or distinct outcomes to therapy [Shipp et al. (2002)]. Many statistical
methods have been developed to select genes for disease diagnosis, prognosis
and therapeutic targets. However, gene selection alone may not be sufficient.
In cancer pharmacogenomics, for instance, cancer drugs are increasingly
designed to target specific pathways to account for the complexity of the
oncogenic process and the complex relationships between genes [Downward
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(2006)]. Metabolic pathways, for example, are defined as a series of chemi-
cal reactions in a living cell that can be activated or inhibited at multiple
points. If a gene at the top of a signaling cascade is selected as a target, it
is not guaranteed that the reaction will be successfully inactivated, because
multiple genes downstream can still be activated or inhibited. Signals are
generally relayed via multiple signaling routes or networks. Even if a branch
of the pathway is completely blocked by inhibition or activation of multiple
genes, the signal may still be relayed through an alternative branch or even
through a different pathway [Bild et al. (2006)]. Downward (2006) pointed
out that targeting a single pathway or a few signaling pathways might not
be sufficient. Thus, the focus is increasingly on identifying both relevant
genes and pathways. Genes and/or gene products generally interact with
one another and they often function together concertedly. Here we propose
a Bayesian model that addresses this question by incorporating informa-
tion of pathway memberships and gene networks in the analysis of DNA
microarray data. Such information is used to define pathway summaries,
specify prior distributions, and structure the MCMC moves.
Several public and commercial databases have been developed to struc-
ture and store the vast amount of biological knowledge accumulated over
the years into functionally or biochemically related groups. These databases
focus on describing signaling, metabolic or regulatory pathways. Some ex-
amples include Gene Ontology (GO) [Ashburner et al. (2000)], Kyoto En-
cyclopedia of Genes and Genomes (KEGG) [Kanehisa and Goto (2000)],
MetaCyc [Krieger et al. (2004)], PathDB, Reactome KnowledgeBase [Joshi-
Tope et al. (2005)], Invitrogen iPath (www.invitrogen.com) and Cell Signal-
ing Technology (CST) Pathway (www.cellsignal.com). The need to integrate
gene expression data with the biological knowledge accumulated in these
databases is well recognized. Several software packages that query pathway
information and overlay DNA microarray data on pathways have been devel-
oped. Nakao et al. (1999) implemented a visualization tool that color-codes
KEGG pathway diagrams to reflect changes in their gene expression levels.
GenMAPP [Dahlquist et al. (2002)] is another graphical tool that allows
visualization of microarray data in the context of biological pathways or
any other functional grouping of genes. Doniger et al. (2003) use GenMAPP
to view genes involved in specific GO terms. Another widely used method
that relates pathways to a set of differentially expressed genes is the gene
set enrichment analysis (GSEA) [Subramanian et al. (2005)]. Given a list of
genes, GSEA computes an enrichment score to reflect the degree to which a
predefined pathway is over-represented at the top or bottom of the ranked
list. These procedures are useful starting points to observe gene expression
changes for known biological processes.
Recent studies have gone a step further and focused on incorporating
pathway information or gene–gene network information into the analysis
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of gene expression data. For example, Park, Hastie and Tibshirani (2007)
have attempted to incorporate GO annotation to predict survival time, first
grouping genes based on their GO membership, calculating the first princi-
pal component to form a super-gene within each cluster and then applying
a Cox model with L1 penalty to identify super-genes, that is, GO terms
related to the outcome. Wei and Li (2007) have considered a small set of
33 preselected signaling pathways and used the implied relationships among
genes to infer differentially expressed genes, and Wei and Li (2008) have ex-
tended this work by including a temporal dimension. Li and Li (2008) and
Pan, Xie and Shen (2010) have proposed different procedures that use the
gene–gene network to build penalties in a regression model for gene selec-
tion. Bayesian approaches have also been developed. Li and Zhang (2010)
have incorporated the dependence structure of transcription factors in a re-
gression model with gene expression outcomes. There, a network is defined
based on the Hamming distance between candidate motifs and used to spec-
ify a Markov random field prior for the motif selection indicator. Telesca
et al. (2008) have proposed a model for the identification of differentially
expressed genes that takes into account the dependence structure among
genes from available pathways while allowing for correction in the gene net-
work topology. Stingo and Vannucci (2011) use a Markov random field prior
that captures the gene–gene interaction network in a discriminant analysis
setting.
These methods use the gene-pathway relationships or gene network infor-
mation to identify either the important pathways or the genes. Our goal is to
develop a more comprehensive method that selects both pathways and genes
using a model that incorporates pathway-gene relationships and gene depen-
dence structures. In order to identify relevant genes and pathways, latent
binary vectors are introduced and updated using a two-stage Metropolis–
Hastings sampling scheme. The gene networks are used to define a Markov
random field prior on the gene selection indicators and to structure the
Markov chain Monte Carlo (MCMC) moves. In addition, the pathway infor-
mation is used to derive pathway expression measures that summarize the
group behavior of genes within pathways. In this paper we make use of the
first latent components obtained by applying partial least squares (PLS)
regressions on the selected genes from each pathway. PLS is an efficient
statistical regression technique that was initially proposed in the chemo-
metrics literature [Wold (1966)] and more recently used for the analysis of
genomic and proteomic data; see Boulesteix and Strimmer (2007). We apply
the model to simulated and real data using the pathway structure from the
KEGG database.
Our simulation studies show that the MRF prior leads to a better separa-
tion between relevant and nonrelevant pathways, and to less false positives
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in a model with fairly small regression coefficients. Other authors have re-
ported similar results. Li and Zhang (2010), in particular, comment on the
effect of the MRF prior on the selection power in their linear regression
setting. They also notice that adding the MRF prior implies a relatively
small increase in computational cost. Wei and Li (2007, 2008) report that
their method is quite effective in identifying genes and modified subnetworks
and that it has higher sensitivity than commonly used procedures that do
not use the pathway structure, with similar and, in some cases, lower false
discovery rates. Furthermore, in our model formulation we use the network
information not only for prior specification but also to structure the MCMC
moves. This is helpful for arriving at promising models faster by proposing
relevant configurations. In real data applications the integration of pathway
information may allow the identification of relevant predictors that could be
missed otherwise, aiding the interpretation of the results, in particular, for
the selected genes that are connected in the MRF, and also improving the
prediction accuracy of selected models.
The paper is organized as follows. Section 2 contains the model formula-
tion and prior specification. Section 3 describes the MCMC procedure and
strategies for posterior inference. In Section 4 performances are evaluated
on simulated data and an application of the method to gene expression data
with survival outcomes is presented. Section 5 concludes the paper with
a brief discussion.
2. Model specification. We describe how we incorporate pathway and
gene network information into a Bayesian modeling framework for gene and
pathway selection. Figure 1 represents a schematic representation of our
approach and model.
2.1. Regression on latent measures of pathway activity. Our goal is to
build a model for identifying pathways related to a particular phenotype
while simultaneously locating genes from these selected pathways that are
involved in the biological process of interest. The data we have available for
analysis consist of the following:
(1) Y , an n× 1 vector of outcomes.
(2) X, an n× p matrix of gene expression levels. Without loss of gener-
ality, X is centered so that its columns sum to 0.
(3) S, a K × p matrix indicating membership of genes in pathways, with
elements skj = 1 if gene j belongs to pathway k, and skj = 0 otherwise.
(4) R, a p×p matrix describing relationships between genes, with rij = 1
if genes i and j have a direct link in the gene network, and rij = 0 otherwise.
The matrices S and R are constructed using information retrieved from
pathway databases; see the application in Section 4.2 for details.
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Fig. 1. Schematic representation of our proposed approach. Information on known path-
ways and gene–gene networks is obtained from available databases. PLS components re-
stricted to known pathways serve as possible regressors to predict a disease outcome, ac-
cording to model (1). The goal of the inference is to identify the pathways to be included
in the model and the genes to be included within those pathways.
Since the goal of the analysis is to study the association between the
response variable and the pathways, we need to derive a score as a measure of
“pathway expression” that summarizes the group behavior of included genes
within pathways. We do this by using the latent components from a PLS
regression of Y on selected subsets of genes from each pathway. A number
of recent studies have, in fact, applied dimension reduction techniques to
capture the group behavior of multiple genes. Pittman et al. (2004), for
instance, first apply k-means clustering to identify subsets of potentially
related genes, then use as regressors the first principal components obtained
from applying principal component analysis (PCA) to each cluster. Bair
et al. (2006) start by removing genes that have low univariate correlation
with the outcome variable, then apply PCA on the remaining genes to form
clusters or conceptual pathways, which are used as regressors. In our method,
instead of attempting to infer conceptual pathways, we use the existing
pathway information. We compute a pathway activity measure by applying
PLS regression of Y on a subset of selected genes from the pathway. PLS
has the advantage of taking into account the covariance between regressors
and the response variable Y , whereas PCA focuses solely on the variability
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in the covariate data. The selection of a subset of gene expressions to form
the PLS components is similar in spirit to the sparse PCA method proposed
by Zou, Hastie and Tibshirani (2006), which selects variables to form the
principal components.
To identify both relevant groups and important genes, we introduce two
binary vector indicators, a K × 1 vector θ for the inclusion of the groups
and a p× 1 vector γ for the inclusion of genes, that is, γj = 1 if gene j is
selected for at least one pathway score, and γj = 0 otherwise. Assuming that
the response Y is continuous, the linear regression model that relates Y to
the selected pathways and genes is
Y = 1α+
Kθ∑
k=1
Tk(γ)βk(γ) + ε, ε∼N (0, σ
2
I),(1)
whereKθ =
∑K
k=1 θk is the number of selected pathways and where Tk(γ) cor-
responds to the first latent PLS component generated based on the expres-
sion levels of selected genes belonging to pathway k, that is, using the Xj ’s
corresponding to skj = 1 and γj = 1. To be more precise, let pathway k
contain pk =
∑p
j=1 skj genes and let pkγ =
∑p
j=1 skjγj denote the number
of selected genes (i.e., genes included in the model) that belong to path-
way k. Then Tk(γ) corresponds to the first latent PLS component generated
by applying PLS to the expression data of the pkγ genes, denoted as Xk(γ),
Tk(γ) =Xk(γ)U1,
where U1 is the pkγ × 1 eigenvector corresponding to the largest eigenvalue
of CxyC
T
xy, with Cxy = cov(Xk(γ), Y ) [see, e.g., Lindgren, Geladi and Wold
(1993)]. Thus, Tk(γ) is an n× 1 vector and βk(γ) is a scalar. Model (1) can
therefore be seen as a PLS regression model with PLS components restricted
to available pathways, and where the goal of the inference is to identify the
pathways to be included in the model, and the genes to be included within
those pathways.
2.2. Models for categorical or censored outcomes. In the construction
above, we have assumed a continuous response. However, our model for-
mulation can easily be extended to handle categorical or censored outcome
variables.
When Y is a categorical variable taking one of G possible values, 0, . . . ,
G− 1, a probit model can be used, as done by Albert and Chib (1993), Sha
et al. (2004) and Kwon et al. (2007). Briefly, each outcome Yi is associated
with a vector (pi,0, . . . , pi,G−1), where pig = P (Yi = g) is the probability that
subject i falls in the gth category. The probabilities pig can be related to the
linear predictors using a data augmentation approach. Let Zi be latent data
corresponding to the unobserved propensities of subject i to belong to one of
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the classes. When the observed outcomes Yi correspond to nominal values,
the relationship between Yi and Zi = (zi,1, . . . , zi,G−1) can be defined as
Yi =

0, if max
1≤l≤G−1
{zi,l} ≤ 0,
g, if max
1≤l≤G−1
{zi,l}> 0 and zi,g = max
1≤l≤G−1
{zi,l}.
(2)
A multivariate normal model can then be used to associate Zi to the pre-
dictors
Zi = 1α+
Kθ∑
k=1
Ti,k(γ)βk(γ) + εi, εi ∼N (0,Σ), i= 1, . . . , n.(3)
If the observed outcomes Yi correspond, instead, to ordinal categories,
the latent variable Zi is defined such that Yi = g if δg < Zi ≤ δg+1, g =
0, . . . ,G − 1, where the boundaries δg are unknown and −∞ = δ0 < δ1 <
· · ·< δG−1 < δG =∞. The latent variable Zi is associated with the predictors
through the linear model
Zi = α+
Kθ∑
k=1
Ti,k(γ)βk(γ) + εi, εi ∼N (0, σ
2), i= 1, . . . , n.(4)
For censored survival outcomes, an accelerated failure time (AFT) model
can be used [Wei (1992); Sha, Tadesse and Vannucci (2006)]. In this case,
the observed data are Yi =min(Ti,Ci) and δi = I{Yi ≤Ci}, where Ti is the
survival time for subject i, Ci is the censoring time, and δi is a censoring
indicator. A data augmentation approach can be used and latent variables Zi
can be introduced such that{
Zi = log(Yi), if δi = 1,
Zi > log(Yi), if δi = 0.
(5)
The AFT model can then be written in terms of the latent Zi similarly to (4)
where the εi’s are independent and identically distributed random variables
that may take one of several parametric forms. Sha, Tadesse and Vannucci
(2006) consider cases where εi follows a normal or a t-distribution.
2.3. Prior for regression parameters. The regression coefficient βk in (1)
measures the effect of the PLS latent component summarizing the effect of
pathway k on the response variable. However, not all pathways are related
to the phenotype and the goal is to identify the predictive ones. Bayesian
methods that use mixture priors for variable selection have been thoroughly
investigated in the literature, in particular, for linear models; see George and
McCulloch (1997) for multiple regression, Brown, Vannucci and Fearn (1998)
for extensions to multivariate responses and Sha et al. (2004) for probit mod-
8 STINGO, CHEN, TADESSE AND VANNUCCI
els. A comprehensive review on features of the selection priors and on compu-
tational aspects of the method can be found in Chipman, George and McCul-
loch (2001). Similarly, we use the latent vector θ to specify a scale mixture
of a normal density and a point mass at zero for the prior on each βk in (1):
βk|θk, σ
2 ∼ θk · N (β0, hσ
2) + (1− θk) · δ0(βk), k = 1, . . . ,K,(6)
where δ0(βk) is a Dirac delta function. The hyperparameter h in (6) regu-
lates, together with the hyperparameters of p(θ,γ|η) defined in Section 2.4
below, the amount of shrinkage in the model. We follow the guidelines pro-
vided by Sha et al. (2004) and specify h in the range of variability of the data
so as to control the ratio of prior to posterior precision. For the intercept
term, α, and the variance, σ2, we take conjugate priors α|σ2 ∼N (α0, h0σ
2)
and σ2 ∼ Inv-Gamma(ν0/2, ν0σ
2
0/2), where α0, β0, h0, h, ν0 and σ
2
0 are to
be elicited.
2.4. Priors for pathway and gene selection indicators. In this section we
define the prior distributions for the pathway selection indicator, θ, and gene
selection indicator, γ. These priors are first defined marginally then jointly,
taking into account some necessary constraints.
Each element of the latent K-vector θ is defined as
θk =
{
1, if pathway k is represented in the model,
0, otherwise
(7)
for k = 1, . . . ,K. We assume independent Bernoulli priors for the θk’s,
p(θ|ϕk) =
K∏
k=1
ϕθkk (1−ϕk)
1−θk ,(8)
where ϕk determines the proportion of pathways expected a priori in the
model. A mixture prior can be further specified for ϕk to achieve a better
discrimination in terms of posterior probabilities between significant and
nonsignificant pathways by inflating p(θk = 0) toward 1 for the nonrelevant
pathways, as first suggested by Lucas, Carvalho, Wang, Bild, Nevins and
West (2006),
p(ϕk) = ρδ0(ϕk) + (1− ρ)B(ϕk|a0, b0),(9)
where B(ϕk|a0, b0) is a Beta density function with parameters a0 and b0.
Since inference on ϕk is not of interest, it can be integrated out to simplify
the MCMC implementation. This leads to the following marginal prior for θ:
p(θ) =
∏
k
[
ρ · (1− θk) + (1− ρ) ·
B(a0 + θk, b0 + 1− θk)
B(a0, b0)
]
,(10)
where B(·, ·) is the Beta function. Prior (10) corresponds to a product of
Bernoulli distributions with parameter ϕ∗k =
a0(1−ρ)
a0+b0
.
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For the latent p-vector γ we specify a prior distribution that is able to take
into account not only the pathway membership of each gene but also the
biological relationships between genes within and across pathways, which
are captured by the matrix R. Following Li and Zhang (2010), we model
these relations using a Markov random field (MRF), where genes are repre-
sented by nodes and relations between genes by edges. A MRF is a graphical
model in which the distribution of a set of random variables follow Markov
properties that can be described by an undirected graph. In particular, two
unconnected genes are considered conditionally independent given all other
genes [Besag (1974)]. Relations on the MRF are represented by the following
probabilities:
p(γj |η, γi, i ∈Nj) =
exp(γjF (γj))
1 + exp(F (γj))
,(11)
where F (γj) = (µ + η
∑
i∈Nj
γi)) and Nj is the set of direct neighbors of
gene j in the MRF using only pathways represented in the model, that is,
pathways with θk = 1. The corresponding global distribution on the MRF is
given by
p(γ|θ, µ, η)∝ exp(µ1′pγ + ηγ
′
Rγ),(12)
with 1p the unit vector of dimension p and R the matrix introduced in
Section 2.1. The parameter µ controls the sparsity of the model, while η
regulates the smoothness of the distribution of γ over the graph by con-
trolling the prior probability of selecting a gene based on how many of its
neighbors are selected. In particular, higher values of η encourage the selec-
tion of genes with neighbors already selected into the model. If a gene does
not have any neighbor, then its prior distribution reduces to an indepen-
dent Bernoulli with parameter p = exp(µ)/[1 + exp(µ)], which is a logistic
transformation of µ.
Here, unlike Li and Zhang (2010), who fix both parameters of the MRF
prior, we specify a hyperprior for η. We give positive probability to values
of η bigger than 0, which is biologically more intuitive than negative values of
this parameter (which would favor neighboring genes to have different inclu-
sion status). Such restriction on the domain of η also minimizes the “phase
transition” problem that typically occurs with MRF parameterizations of
type (11), where the dimension of the selected model increases massively
for small increments of η. When the phase transition occurs the number of
selected genes increases substantially. Here, after having detected the phase
transition value ηPT , by simulating from (12) over a grid of η values, we
specify a Beta distribution Beta(c0, d0) on η/ηPT .
Constraints need to be imposed to ensure both interpretability and iden-
tifiability of the model. We essentially want to avoid the following:
(1) empty pathways, that is, selecting a pathway but none of its member
genes;
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(2) orphan genes, that is, selecting a gene but none of the pathways that
contain it;
(3) selection of identical subsets of genes by different pathways, a situ-
ation that generates identical values Tk(γ) and Tk′(γ) to be included in the
model.
These constraints imply that some combinations of θ and γ values are not
allowed. The joint prior probability for (θ,γ) taking into account these con-
straints is given by
p(θ,γ|η)∝

K∏
k=1
ϕ∗θkk (1− ϕ
∗
k)
1−θk exp(µ1′pγ + ηγ
′
Rγ),
for valid configurations,
0, for invalid configurations.
3. Model fitting. We now describe our MCMC procedure to fit the model
and discuss strategies for posterior inference with huge posterior spaces, as
in this model. In the Bayesian literature on variable selection for standard
linear regression models stochastic search algorithms have been designed to
explore the posterior space, and have been successfully employed in genomic
applications with prohibitive settings, handling models with thousands of
genes. A key to these applications is the assumption of sparsity of the model,
that is, the belief that the response is associated with a small number of
regressors. A stochastic search then allows one to explore the posterior space
in an effective way, quickly finding the most probable configurations, that is,
those corresponding to coefficients with high marginal probabilities, while
spending less time in regions with low posterior probability.
We describe below the MCMC algorithm we have designed for our prob-
lem. In particular, borrowing from the literature on stochastic searches for
variable selection, we work with a marginalized model and design a Metro-
polis–Hastings algorithm that updates the indicator parameters for the in-
clusion of pathways and genes with a set of moves that add and/or delete
a single gene and a single pathway. Also, we update the parameter η of
the MRF from its posterior distribution by employing the general method
proposed by Møller et al. (2006). In Stingo et al. (2011) we discuss how
our Bayesian stochastic search variable selection kernel generates an ergodic
Markov chain over the restricted space. In applications, we have found that
a good way to asses if the stochastic exploration can be considered satisfac-
tory is to check the concordance of the posterior probabilities obtained from
different chains started from different initial points.
3.1. Marginal posterior probabilities. The model parameters consist of
(α,β, σ2,γ,θ, η). The MCMC procedure can be made more efficient by
integrating out some of the parameters. Here, we integrate out the regression
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parameters, α, β and σ2. This leads to a multivariate t-distribution
f(Y |T,θ,γ)∼Tν0(α01n+T(θ,γ)β0, σ
2
0(In+h01n1
′
n+T(θ,γ)Σ0T
′
(θ,γ))),(13)
with ν0 degrees of freedom and 1n an n-vector of ones, and whereΣ0 = hIKθ ,
with In the n × n identity matrix, and T(θ,γ) the n ×Kθ matrix derived
from the first PLS latent components for the selected pathways using the
selected genes. In the notation (13) the two arguments of the t-distribution
represent the mean and the scale parameter of the distribution, respectively.
The posterior probability distribution of the pathway and gene selection
indicators is then given by
f(θ,γ, η|T, Y )∝ f(Y |T,θ,γ) · p(θ,γ|η) · p(η).(14)
3.2. MCMC sampling. The MCMC steps consist of the following: (I)
sampling pathway and gene selection indicators from p(θ,γ|rest); (II) sam-
pling the MRF parameter from p(η|rest); (III) sampling additional parame-
ters introduced when fitting probit models for categorical outcomes or AFT
models for survival data.
(I) The parameters (θ,γ) are updated using a Metropolis–Hastings algo-
rithm in a two-stage sampling scheme. The pathway-gene relationships
are used to structure the moves and account for the constraints spec-
ified in Section 2.4. Details of the MCMC moves to update (θ,γ) are
given in Stingo et al. (2011). They consist of randomly choosing one
of the following move types:
(1) change the inclusion status of gene and pathway by randomly
choosing between adding a pathway and a gene or removing them
both;
(2) change the inclusion status of gene but not pathway by randomly
choosing between adding a gene or removing a gene;
(3) change the inclusion status of pathway but not gene by randomly
choosing between adding a pathway or removing a pathway.
(II) At this step we want to draw the MRF parameter η from the posterior
density p(η|γ)∝ p(η)p(γ|η). The prior distribution on γ is of the form
p(γ|η) = qη(γ)/Zη(15)
with unnormalized density qη(γ) and a normalizing constant Zη which
is not available analytically. When calculating the Metropolis–Hastings
ratio to determine the acceptance probability of a new value ηp,
H(ηp|ηo) =
p(ηp)qηp(γ)q(η
o|ηp)
p(ηo)qηo(γ)q(ηp|ηo)
/
Zηp
Zηo
,(16)
with ηo the current value for η, one needs to take into account that
Zηp/Zηo 6= 1. Following Møller et al. (2006), we introduce an auxiliary
12 STINGO, CHEN, TADESSE AND VANNUCCI
variable w, defined on the same state space as that of γ, which has
conditional density f(w|η,γ), and consider the posterior p(η,w|γ) ∝
f(w|η,γ)p(η)qη(γ)/Zη , which of course still involves the unknown Zη .
Obviously, marginalization over w of p(η,w|γ) gives the desired dis-
tribution p(η|γ). Now, if (ηo,wo) is the current state of the algo-
rithm, we first propose ηp with density q(ηp|ηo), then wp with den-
sity q(wp|wo, ηp, ηo). As usual, the choice of these proposal densities
is arbitrary from the point of view of the equilibrium distribution of
the chain of η values. The choice of f(w|η,γ) is also arbitrary. The
key idea of the method proposed by Møller et al. (2006) is to take the
proposal density for the auxiliary variable w to be of the same form
as (15), but dependent on ηp rather than ηo, that is,
q(wp|wo, ηp, ηo) = p(wp|ηp) = qηp(w
p)/Zηp .(17)
Then the Metropolis–Hastings ratio becomes
H(ηp,wp|ηo,wo) =
f(wp|ηp,γ)p(ηp)qηp(γ)qηo(w
o)q(ηo|ηp)
f(wo|ηo,γ)p(ηo)qηo(γ)qηp(wp)q(ηp|ηo)
,(18)
and no longer depends on Zηp/Zηo . The new value w
p for the auxiliary
variable w is drawn from (17) by perfect simulation using the algorithm
proposed by Propp and Wilson (1996).
(III) In the case of classification or survival outcomes, the augmented data Z
need to be updated from their full conditionals using Gibbs sampling;
see Sha et al. (2004), Sha, Tadesse and Vannucci (2006) and Kwon
et al. (2007) for details.
3.3. Posterior inference. The MCMC procedure results in a list of vis-
ited models with included pathways indexed by θ and selected genes indexed
by γ, and their corresponding relative posterior probabilities. Pathway selec-
tion can be based on the marginal posterior probabilities p(θk|T, Y ). A sim-
ple strategy is to compute Monte-Carlo estimates by counting the number of
appearances of each pathway across the visited models. Relevant pathways
are identified as those with largest marginal posterior probabilities. Then
relevant genes from these pathways are identified based on their marginal
posterior probabilities conditional on the inclusion of a pathway of inter-
est, p(γj|T, Y, I{θkskj = 1}). An alternative inference for gene selection is
to focus on a subset of pathways, P , and consider the marginal posterior
probability conditional on at least one pathway the gene belongs to be-
ing represented in the model, p(γj |T, Y, I{
∑
k∈P θkskj > 0}). We note that
Rao–Blackwellized estimates have been employed in standard linear regres-
sion models, in place of frequency estimates, by averaging the full condi-
tional posterior probabilities of the inclusion indicators. These estimates are
A BAYESIAN MODEL FOR PATHWAY AND GENE SELECTION 13
computationally quite expensive, though they may have better precision, as
noted by Guan and Stephens (2011). Because of our strategy for inference,
that selects first pathways and then genes conditional on selected pathways,
Rao–Blackwellized estimates of marginal probabilities may not be straight-
forward to derive. In all simulations and examples reported in this paper we
have obtained satisfactory results by simply estimating the marginal poste-
rior probabilities with the corresponding relative frequencies of inclusion in
the visited models.
Inference for a new set of observations, (Xf , Yf ), can be done via least
squares prediction, Ŷf = 1nα˜+Tf(θ,γ)β˜(θ,γ), where Tf(θ,γ) is the first prin-
cipal component based on selected genes from relevant pathways and where
α˜ = Y¯ and β˜(θ,γ) = (T
′
(θ,γ)T(θ,γ) + h
−1
IKθ)
−1
T
′
(θ,γ)Y , with Y the response
variable in the training and T(θ,γ) the scores obtained from the training
data using selected pathways and genes included in the model. Note that
for prediction purposes, since we do not know the future Yf , a PLS regression
cannot be fit. Therefore, we generate Tf(θ,γ) by considering the first latent
component obtained by applying PCA to each selected pathway using the
included genes.
In the case of categorical or censored survival outcomes, the sampled
latent variables Z would be used to estimate Ẑf , then the correspondence
between Z and the observed outcome outlined in Section 2.2 can be invoked
to predict Yf [Sha et al. (2004, 2006); Kwon et al. (2007)].
4. Application. We assess performances on simulated data, then illus-
trate an application to microarrays using the KEGG pathway database to
define the MRF.
4.1. Simulation studies. We investigated the performance of our model
using simulated data based on the gene-pathway relations, S, and gene net-
work, R, of 70 pathways and 1,098 genes from the KEGG database. The
relevant pathways were defined by selecting 4 pathways at random. For each
of the 4 selected pathways, one gene was picked at random and its direct
neighbors that belong to the selected pathways were chosen. This resulted
in the selection of 4 pathways and 15 genes: 7 out of 30 from the first
pathway, 3 out of 35 from the second, 3 out of 105 from the third, and 2
out of 47 from the fourth pathway. Gene expressions for n = 100 samples
were simulated for these 15 genes using an approach similar to Li and Li
(2008). This was accomplished by first creating an ordering among the 15
selected genes by changing the undirected edges in the gene networks into
directed edges. The first node on the ordering, which we denote by XF1 , was
selected from each pathway and drawn from a standard normal distribu-
tion; note that this node has no parents. Then all child nodes directly con-
nected only to XF1 and denoted by XF2 were drawn from XF2 ∼N (XF1ρ,1).
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Subsequent child nodes at generation j, XFj , were drawn using all parents
from XFj ∼ N (ρXpa(Fj)1|pa(Fj)|,1), where pa(Fj) indicates the set of par-
ents of node j and Xpa(Fj) is a matrix containing the expressions of all the
|pa(Fj)| parents for node j. The expression levels of the remaining 1,073
genes deemed irrelevant were simulated from a standard normal density.
The response variables for the n= 100 samples were generated from
Yi =
15∑
j=1
Xijβ + εi, εi ∼N (0,1), i= 1, . . . ,100.
For the first data set we set β =±0.5, with the same sign for genes belonging
to the same pathways. For the second and third data sets we used β =±1
and β =±1.5, respectively. Note how the generating process is different from
model (1) being fit.
We report results obtained by choosing, when possible, hyperparameters
that lead to weakly informative prior distributions. A vague prior is assigned
to the intercept α by setting h0 to a large value tending to ∞. For σ
2, the
shape parameter can be set to ν0/2 = 3, the smallest integer such that the
variance of the inverse-gamma distribution exists, and the scale parame-
ter ν0σ
2
0/2 can be chosen to yield a weakly informative prior. For the vector
of regression coefficients, βk, we set the prior mean to β0 = 0 and choose h
in the range of variability of the covariates, as suggested in Section 2.3.
Specifically, we set h0 = 10
6, α0 = β0 = 0, ν0σ0/2 = 0.5, and h = 0.02. For
the pathway selection indicators, θk, we set ϕ
∗
k = 0.01. As for the prior at the
gene level, we set µ=−3.5, corresponding to setting the proportion of genes
expected a priori in the model to, at least, 3% of the total number of genes.
Parameters ϕ∗k and µ influence the sparsity of the model and consequently
the magnitude of the marginal posterior probabilities. Some sensitivity is,
of course, to be expected. However, in our simulations we have noticed that
the ordering of pathways and genes based on posterior probability remains
roughly the same and, therefore, the final selections are unchanged as long
as one adjusts the threshold on the posterior probabilities. Also, for the hy-
perprior on η, we set ηPT = 0.092, to avoid the phase transition problem,
and c0 = 5 and d0 = 2, to obtain a prior distribution that favors bigger val-
ues of η in the interval 0 ≤ η ≤ ηPT . In our simulations we did not notice
sensitivity to the specification of c0 and d0.
The MCMC sampler was run for 300,000 iterations with the first 50,000
used as burn-in.We computed the marginal posterior probabilities for pathway
selection, p(θk = 1|Y,T), and the conditional posterior probabilities for gene
selection given a subset of selected pathways, p(γj |T, Y, I{
∑
k∈P θkskj > 0}).
Figure 2 displays the marginal posterior probabilities of inclusion for all 70
pathways and the conditional posterior probabilities of inclusion for all 1,098
genes.
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Fig. 2. Simulated data: Marginal posterior probabilities for pathway selection,
p(θk|T, Y ), and conditional posterior probabilities for gene selection, p(γj|T, Y,
I{
∑
k∈P θkskj > 0}), for the three simulated data sets. Open circles indicate pathways and
genes used to generate the outcome variable.
Important pathways and genes can be selected as those with highest pos-
terior probabilities. For example, in all 3 scenarios all four relevant pathways
were selected with a marginal posterior probability cutoff of 0.8. Reducing
the selection threshold to a marginal posterior probability of 0.5 pulls in
two false positive pathways, for all the three simulated scenarios considered.
One of the false positives is the pathway with index 17 in Figure 2, which
contains more than 100 genes. A closer investigation of the MCMC output
reveals that different subsets of its member genes are selected whenever it
is included in the model, resulting in a high marginal posterior of inclusion
for the pathway but low marginal posterior probabilities for all its mem-
ber genes. The second false positive pathway appears to be selected often
because it contains two or three of the relevant genes that were used to
simulate the response variable and were also included in the model with
high marginal posterior probabilities; all its other member genes have very
low probabilities of selection. As expected, the identification of the relevant
16 STINGO, CHEN, TADESSE AND VANNUCCI
genes is easier when the signal-to-noise ratio is higher. Conditional upon the
best 4 selected pathways, a marginal posterior probability cutoff of 0.5 on
the marginal probability of gene inclusion leads to the selection of 7, 8 and 8
relevant genes, for the three scenarios, respectively, and no false positives.
With a marginal probability threshold of 0.1, 14 of the relevant genes are se-
lected with 4 false positives for the scenario with β =±0.5, while 13 relevant
genes are selected with only two false positives for the simulated data with
β =±1. In the simulated setting with β =±1.5 all the 15 relevant genes are
selected without any false positive at a threshold of 0.12.
Generally speaking, the effect of the MRF prior depends on the concor-
dance of the prior network with the data. For the simulated data, we found
that the model with the MRF prior, compared to the same model without the
MRF, performs better in terms of pathway selection, as it provides a clearer
separation between relevant and nonrelevant pathways. In particular, the
average difference, over the three scenarios, between the relevant pathway
with the lowest posterior probability and the nonrelevant pathway with the
highest posterior probability is 0.28, while without the MRF prior it is only
0.18. In addition, we have observed increased sensitivity of the MRF prior in
selecting the true variables. For example, for the simulated case with β±1.5,
in order to select all 15 relevant genes, the marginal probability cutoff must
be reduced to 0.088 at the expense of including 3 false positives. Other au-
thors have reported similar results [Li and Zhang (2010)]. In the real data
application we describe below, employing information on gene–gene net-
works aids the interpretation of the results, in particular, for those selected
genes that are connected in the MRF, and improves the prediction accuracy.
4.2. Application to microarray data. We consider the van’t Veer et al.
(2002) breast cancer microarray data.2 Gene expression measures were col-
lected on each patient using DNA microarray with 24,481 probes. Missing
expressions were imputed using a k-nearest neighbor algorithm with k = 10.
The procedure consists of identifying the k closest genes to the one with
missing expression in array j using the other n− 1 arrays, then imputing
the missing value by the average expression of the k neighbors [Troyanskaya
et al. (2001)]. We focus on the 76 sporadic lymph-node-negative patients, 33
of whom developed distant metastasis within 5 years; the remaining 43 are
viewed as censored cases. We randomly split the patients into a training set
of 38 samples and a test set of the same size using a fairly balanced split of
metastatic/nonmetastatic cases. The goal is to identify a subset of pathways
and genes that can predict time to distant metastasis.
The gene network and pathway information were obtained from the KEGG
database. This was accomplished by mapping probes to pathways using the
2Available at www.rii.com/publications/2002/vantveer.htm.
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links between pathway node identifiers and LocusLink ID. Using the R pack-
age KEGGgraph [Zhang and Wiemann (2009)], we first downloaded the gene
network for each pathway, then merged all networks into a single one with
all genes. A total of 196 pathways and 3,592 probes were included in the
analysis, with each pathway containing multiple genes and with most genes
associated with several pathways.
We ran two MCMC chains with different starting numbers of included
variables, 50 and 80, respectively. We used 600,000 iterations with a burn-in
of 100,000 iterations. We incorporated the first latent vector of the PLS for
each pathway into the analysis as described in Section 2.1 and set the number
of pathways expected a priori in the model to 10% of the total number. For
the gene selection, we set the hyperparameter of the Markov random field
to µ = −3.5, indicating that a priori at least 3% of genes are expected to
be selected. We set ηPT = 0.09, to avoid the phase transition problem, and
c0 = 1 and d0 = 1, to obtain a noninformative prior distribution. A sensitivity
analysis showed that the posterior inference is not affected by different values
of c0 and d0. We set α0 = β0 = 0, h0 = 10
6 and h= 0.1 for the prior on the
regression parameters and obtained a vague prior for σ2 by choosing ν0/2 = 3
and ν0σ
2
0/2 = 0.5.
The trace plots for the number of included pathways and the number of
selected genes showed good mixing (figures not shown). The MCMC sam-
plers mostly visited models with 20–45 pathways and 50–90 genes. To assess
the agreement of the results between the two chains, we looked at the cor-
relation between the marginal posterior probabilities for pathway selection,
p(θk|T, Y ), and found good concordance between the two MCMC chains
with a correlation coefficient of 0.9933. Concordance among the marginal
posterior probabilities was confirmed by looking at a scatter plot of p(θk|T, Y )
across the two MCMC chains (figure not shown).
The model also showed good predictive performance. Sha, Tadesse and
Vannucci (2006) already analyzed these data using an AFT model with 3,839
probes as predictors and obtained a predictive MSE of 1.9317 using the 11
probe sets with highest marginal probabilities. Our model incorporating
pathway information achieved a predictive MSE of 1.4497 on the validation
set, using 12 selected pathways and 41 probe sets with highest posterior
probabilities. The selected pathways and genes are clearly indicated in the
marginal posterior probability plots displayed in Figure 3. If we increase the
marginal probability thresholds for selection and consider a model with 7
selected pathways and 14 genes, to make the comparison more fair with the
results of Sha, Tadesse and Vannucci (2006), we obtain a MSE of 1.7614.
As a reminder, our model selects relevant pathways and relevant genes si-
multaneously, while the model of Sha, Tadesse and Vannucci (2006) selects
genes only. Of course, one can always select pathways post-hoc, as those
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Fig. 3. Microarray data: Plot ( a): Marginal posterior probabilities for pathway selection,
p(θk|T, Y ). The 12 pathways with largest probabilities are marked with symbols. Plot (b):
Conditional posterior probabilities for gene selection, p(γj |T, Y, I{
∑
k∈P θkskj > 0}). The
41 probes with largest probability that belong to the 12 selected pathways in plot ( a) are
marked with ∆.
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Table 1
The 41 selected genes divided by islands and with associated pathway indices
(in parenthesis)
Singleton genes (no direct neighbor selected)
ACACB (10), C4A (8, 12), CALM1 (10), CCNB2 (5), CD4 (7), CDC2 (5), CLDN11
(7), FZD9 (11), GYS2 (10), HIST1H2BN (12), IFNA7 (3), NFASC (7), NRCAM (7),
PCK1 (10), PFKP (10), PPARGC1A (10), PXN (9)
Island 1
ACTB (9), ACTG1 (9), ITGA1 (9), ITGA7 (9), ITGB3 (9), ITGB4 (9), ITGB6 (9),
ITGB8 (7, 10), MYL5 (9), MYL9 (9), PDPK1 (10), PIK3CD (9, 10, 11), PLA2G4A
(2), PLCG1 (11), PRKCA (2, 11), PRKY (2, 10), PRKY (2, 10), PTGS2 (11), SOCS3
(10)
Island 2
ACVR1B (2, 3, 11), ACVR1B (2, 3, 11), TGFB3 (2, 3, 5, 11)
Island 3
ENTPD3 (1), GMPS (1)
Notes: The pathway indices correspond to the following: 1-Purine metabolism, 2-
MAPK signaling pathway, 3-Cytokine–cytokine receptor interaction, 4-Neuroactive ligand-
receptor interaction, 5-Cell cycle, 6-Axon guidance, 7-Cell adhesion molecules (CAMs),
8-Complement and coagulation cascades, 9-Regulation of actin cytoskeleton, 10-Insulin
signaling pathway, 11-Pathways in cancer, 12-Systemic lupus erythematosus.
that contain the selected genes. However, as single genes belong to multiple
pathways, we expect our approach to give a more precise selection.
From a practical point of view, researchers can use the posterior probabil-
ities produced by our selection algorithm as a way to prioritize the relevant
pathways and genes for further experimental work. For example, the genes
corresponding to the best 41 selected probe sets, conditional upon the best
12 selected pathways, are listed in Table 1 divided by islands, which corre-
spond to sets of connected genes in the Markov random field. The islands
help with the biological interpretation by locating relevant branches of path-
ways. A subset of the selected pathways along with islands and singletons are
displayed in Figure 4. Several of the identified pathways are involved in tu-
mor formation and progression. For instance, the mitogen-activated protein
kinase (MAPK) signaling pathway, involved in various cellular functions,
including cell proliferation, differentiation and migration, has been impli-
cated in breast cancer metastasis [Lee et al. (2007)]. The KEGG pathway
in cancers was also selected with high posterior probability. Other inter-
esting pathways are the insulin signaling pathway, which has been linked
to the development, progression and outcome of breast cancer, and purine
metabolism, involved in nucleotide biosynthesis and affects cell cycle activity
of tumor cells.
In addition, several genes with known association to breast cancer were
also selected. Protein kinase C alpha (PKCA), which belongs to the MAPK
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Fig. 4. Microarray data: Graphical representation of a subset of selected pathways with
islands and singletons. The genes in the islands are listed in Table 1.
pathway and the KEGG pathways in cancer, has been reported to play
roles in many different cellular processes, including cell functions associ-
ated with breast cancer progression. It has been shown to be overexpressed
in some antiestrogen resistant breast cancer cell lines and to be involved
in the growth of tamoxifen resistant human breast cancer cells [Frankel
et al. (2007)]. Patients with PKCA-positive tumors have been shown to have
worse survival than patients with PKCA-negative tumors, independently of
other factors [Lønne et al. (2010)]. Prostaglandin-endoperoxide synthase-2
(PTGS2, also known as cyclooxygenase-2 or COX2) has also been related
to breast cancer. Denkert, Winzer and Hauptmann (2004) observed COX2
overexpression in breast cancer and strong association with indicators of
poor prognosis, such as lymph node metastasis, poor differentiation and
large tumor size. This was further confirmed by Gupta et al. (2007), who
showed that the expression of COX2 in human breast cancer cells facilitates
the assembly of new tumor blood vessels, the release of tumor cells into the
circulation, and the breaching of lung capillaries by circulating tumor cells
to seed pulmonary metastasis. This is an important finding, as the major-
ity of breast cancer deaths result from metastases rather than direct effects
of the primary tumor. Another gene previously shown to be predictive of
breast cancer lung metastasis is integrin, beta-8 (ITGB8) [Landemaine et al.
A BAYESIAN MODEL FOR PATHWAY AND GENE SELECTION 21
(2008)]. We also identified integrin, beta-4 (ITGB4) which regulates key sig-
naling pathways related to carcinoma progression, and is linked to aggressive
tumor behavior and poor prognosis in certain breast cancer subtypes [Guo
et al. (2006)].
5. Discussion. We have proposed a model that incorporates biological
knowledge from pathway databases into the analysis of DNA microarrays to
identify pathways and genes related to a phenotype. Information on pathway
membership and gene networks are used to define pathway summaries, spec-
ify prior distributions that account for the dependence structure between
genes, and define the MCMC moves to fit the model. The gene network
prior and the synthesis of the pathway information through PLS bring in
additional information that is especially useful in microarray data, due to the
low sample size and large measurement error. Performances of the method
were evaluated on simulated data and a breast cancer gene expression study
with survival outcomes was used to illustrate its application.
Our simulation studies show the effect of the MRF prior on the posterior
inference. In general, as expected, the effect of the prior depends on the
data and, in particular, on the concordance of the prior network with the
data. In our simulations, employing the MRF prior allows us to achieve
a better separation of the relevant pathways from those not relevant (in
particular, we have found a larger average difference, over three scenarios,
between the relevant pathway with the lowest posterior probability and the
nonrelevant pathway with the highest posterior probability). In addition, in
the simulated setting with fairly small regression coefficients the model with
the MRF prior was able to select all the correct genes without any false
positive, while the model without MRF includes 3 false positives. Other
authors have reported improvements on selection power and sensitivity with
respect to commonly used procedures that do not use the pathway structure,
with similar, and in some cases, lower false discovery rates. In addition, in
our formulation of the model we have used biological information not only for
prior specification but also to structure the MCMC moves. This is helpful in
arriving at promising models avoiding visiting invalid configurations. Finally,
in real data applications, we have found that employing information on gene–
gene networks can lead to the selection of significant genes that would have
been missed otherwise, aiding the interpretation of the results, and achieving
better predictions compared to models that do not treat genes as connected
elements that work in groups or pathways.
Several MRF priors for gene selection indicators have been proposed in
the literature. It is interesting to compare the parametrization of the MRF
used in this paper and in Li and Zhang (2010) to the parametrization used
in Wei and Li (2007, 2008), where the prior on γ is defined as
P (γ|·)∝ exp(dn1 − gn01),(19)
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where n1 is the number of selected genes and n01 is the number of edges
linking genes with different values of γj , that is, edges linking included and
nonincluded genes among all pathways,
n1 =
p∑
j=1
γj, n01 =
1
2
p∑
i=1
[
p∑
j=1
rij −
∣∣∣∣∣
p∑
j=1
rij(1− γi)−
p∑
j=1
rijγj
∣∣∣∣∣
]
.
While d plays the same role as µ in (12), the parametrization using g has
a different effect from η on the probability of selection of a gene. This is evi-
dent from the conditional probability P (γj |·, γi, i ∈Nj) =
exp(γjF (γj))
1+exp(F (γj ))
, where
F (γj) = d+g
∑
i∈Nj
(2γi−1). Higher values of g encourage neighboring genes
to take on the same γj value, and, consequently, genes with nonselected
neighbors have lower prior probability of being selected than genes with no
neighbors. We felt that parametrization (12) was a better choice for our pur-
poses. First, in a context of sparsity, where only few nodes are supposed to
take value 1, a prior that assigns larger probability of inclusion to genes with
selected neighbors than to isolated genes seems more appropriate. Second,
the exact simulation algorithm of Propp and Wilson (1996) cannot be used
to simulate from (19). While any other method to draw from (19) would be
acceptable, as said by Møller et al. (2006), Markov chain methods, to sam-
ple from a MRF, require to check at each step that the chain has converged
to the equilibrium distribution, to avoid introducing additional undesirable
stochasticity. On the other hand, one advantage of parametrization (19) is
that no phase transition problem is associated to the distribution.
Pathway databases are incomplete and the gene network information is
often unavailable for many genes. Thus, there may be situations where the
dependence structure and the MRF prior specification on the gene selection
indicator, γ, cannot be used for all genes. When the only information avail-
able is the pathway membership of genes, the prior on γ could be elicited to
capture other interesting characteristics. For example, a gene can have a pri-
ori higher probability of being selected when several pathways that contain it
are included in the model. We may also want to avoid favoring the selection
of a large pathway just because of its size. In such cases, conditional on θ,
independent Bernoulli priors can be specified for γj relating the probability
of selection to the proportion of included pathways that contain gene j, ad-
justing for the pathway sizes, pk, that is, γj|θ ∼ Bernoulli(c ·
∑K
k=1 θkskj/pk∑K
k=1 skj/pk
),
with c a hyperparameter to be elicited.
In our approach we have made use of PLS components as summary mea-
sures of the expression of genes belonging to known pathways and then
applied a fully Bayesian approach for the selection of the pathways to be
included in the model, and the genes to be included within those pathways.
Penalized techniques, including lasso [Tibshirani (1996)], elastic net [Zou
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and Hastie (2005)] and group lasso [Yuan and Lin (2006)] have been stud-
ied extensively in the literature and have been successfully applied to gene
expression data. The group lasso, in particular, defines sets of variables,
then selects either all the variables in the group or none of them. Recently,
a modification of the method was proposed by Friedman, Hastie and Tib-
shirani (2010) using a more general penalty that yields sparsity at both the
group and individual feature levels to select groups and predictors within
each group. Our understanding of group lasso is that the method works
best in situations where variables belonging to the same group are highly
correlated, while covariates in different groups do not exhibit high correla-
tion. However, genes belonging to the same pathway often do not exhibit
high correlation in their expression levels. Also, in our case there are genes
belonging to different pathways that have high correlation, as well as genes
that belong to more than one pathway. Initial investigations suggest that, in
terms of prediction MSE, Bayesian formulations of lasso methods perform
similarly to and, in some cases, better than the frequentist lasso [see, e.g.,
Kyung et al. (2010)]. Particularly relevant to our approach is the work of
Guan and Stephens (2011), who apply Bayesian variable selection (BVS)
and stochastic search methods in a regression model for genome-wide data.
In simulations they find that, in spite of the apparent computational chal-
lenges, BVS produces better power and predictive performance compared
with standard lasso techniques.
SUPPLEMENTARY MATERIAL
Supplement (DOI: 10.1214/11-AOAS463SUPP; .pdf). Description of the
MCMC steps for (θ,γ) and discussion on ergodicity of the Markov chain on
the restricted space.
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